



OptumRx has partnered with CoverMyMeds to receive prior authorization requests, saving you time and often delivering real-time determinations.

Visit go.covermymeds.com/OptumRx to begin using this free service.

Please note: All information below is required to process this request.

Mon-Fri: 5am to 10pm Pacific / Sat: 6am to 3pm Pacific

Fasenra™ Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)

Select the diagnosis below:

Severe asthma

Other diagnosis: _____ ICD-10 Code(s): _____

Clinical Information:

Does the patient have asthma of eosinophilic phenotype as defined by baseline blood eosinophil level greater than or equal to 150 cells per microliter? Yes No

Has the patient had at least two or more asthma exacerbations requiring systemic corticosteroids within the past 12months? Yes No

Has the patient had prior intubation for an asthma exacerbation? Yes No

Has the patient had a prior asthma-related hospitalization within the past 12 months? Yes No

Select if the patient is currently being treated with one of the following unless there is a contraindication or intolerance to these medications:

- High-dose inhaled corticosteroid (ICS) [e.g., greater than 500 mcg fluticasone propionate equivalent/day] with one additional asthma controller medication [e.g., leukotriene receptor antagonist, long-acting beta-2 agonist (LABA), theophylline]
- One maximally-dosed combination ICS/LABA product [e.g., Advair (fluticasone propionate/salmeterol), Dulera (mometasone/formoterol), Symbicort (budesonide/formoterol)]

Is Fasentra prescribed by or in consultation with a pulmonologist or allergy/immunology specialist? Yes No

Reauthorization:

If this is a reauthorization request, answer the following questions:

Is there documentation the patient has had a positive clinical response (e.g., reduction in exacerbations)? Yes No

Has the patient had a prior asthma-related hospitalization within the past 12 months? Yes No

Select if the patient is currently being treated with one of the following unless there is a contraindication or intolerance to these medications:

- Inhaled corticosteroid (ICS) with additional asthma controller medication [e.g., leukotriene receptor antagonist, long-acting beta-2 agonist (LABA), theophylline]
- Combination ICS/LABA product [e.g., Advair (fluticasone propionate/salmeterol), Dulera (mometasone/formoterol), Symbicort (budesonide/formoterol)]

Is Fasentra prescribed by or in consultation with a pulmonologist or allergy/immunology specialist? Yes No

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
 For urgent or expedited requests please call 1-800-711-4555.
 This form may be used for non-urgent requests and faxed to 1-800-527-0531.

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.**
 Office use only: Fasentra_Comm_2018Jun-W